Encapsulated liver cell composition
Microcapsules including a capsule shell encapsulating a suspension of a therapeutically effective amount of liver cells in physical contact with a liver cell stimulating amount of erythropoietin.
1. A method for introducing liver cells into a subject in need thereof comprising: administering microcapsules comprising a capsule shell encapsulating a suspension of liver cells embedded in a biocompatible matrix with erythropoietin into a subject in need thereof, wherein the concentration of liver cells in the suspension is 10 4 to 10 8 liver cells/ml and the concentration of erythropoietin in the suspension is 10 −7 to 10 −2 U/ml, wherein the administering step occurs by parenteral administration of said microcapsules under the liver capsule, into the liver, into the liver pulp, into the splenic artery, or into the portal vein of the subject, and wherein the erythropoietin maintains ATP/ADP ratios at an increased rate in said liver cells as compared to liver cells identically capsulated except without said erythropoietin.
2. The method according to claim 1 , wherein the liver cells are selected from the group consisting of hepatic precursor cells, hepatic stem cells, hepatoblasts, endothelial cells and hepatocytes.
3. The method according to claim 1 , wherein the liver cells are obtained from adult liver, fetal liver, neonatal liver or liver cell cultures.
4. The method according to claim 1 , wherein the liver cells are human liver cells, non-human primate liver cells, pig liver cells, dog liver cells, cat liver cells, rabbit liver cells, mouse liver cells or rat liver cells.
5. The method according to claim 1 , wherein the microcapsules have an average diameter from 100 to 700 μm.
6. The method according to claim 1 , wherein the liver cells have an average diameter of 8 to 14 μm.
7. The method according to claim 1 , wherein the concentration of erythropoietin in the suspension is 10 −7 to 10 −3 U/ml.
8. The method according to claim 1 , wherein erythropoietin is wild type erythropoietin or recombinant erythropoietin.
9. The method according to claim 1 , wherein the capsule shell is made from a biocompatible material selected from the group consisting of alginate, alginate-chitosan (AC), alginate-poly-L-lysine (APA), thermogelation-polymer and PEG-hydrogel.
10. The method according to claim 1 , wherein in addition to the liver cells at least one further cell type is present in the microcapsule.
11. The method according to claim 1 , wherein the microcapsules are coated.